MDM Templates
COPD Exacerbation — Moderate
Patient with known COPD (FEV1 ***) presents with *** days of increased dyspnea, sputum volume/purulence, and/or cough. Well appearing with respiratory rate ***, O2 saturation *** on *** liters, and no acute distress. Exam shows no accessory muscle use at rest, able to speak full sentences, and breath sounds are diminished but not silent. Chest X-ray shows no acute infiltrate or pneumothorax.
This is an acute exacerbation responsive to bronchodilators and corticosteroids without evidence of respiratory failure, pneumonia, or other life-threatening process. History and exam lower suspicion for acute coronary syndrome, pulmonary embolism, and pneumonia as primary etiology.
Plan: Dual bronchodilator nebulizer therapy initiated (albuterol/ipratropium) with repeat dosing every 30–60 minutes for first 2 hours based on response. Prednisone 40 mg daily for 5 days started. Antibiotics added if sputum purulence and increased volume present — azithromycin 500 mg daily for 3 days preferred. Patient given rescue inhaler and instructed in MDI technique. Disposition: Discharge home with PCP follow-up within 1 week. Return precautions for worsening dyspnea, inability to maintain oxygen saturation, or inability to take oral medications.
COPD Exacerbation — Severe/ICU
Patient with advanced COPD presents with severe dyspnea at rest, unable to speak full sentences, and appearing in significant respiratory distress. Respiratory rate ***, accessory muscle use prominent, retractions present. Initial O2 saturation *** on supplemental oxygen, with inadequate response to initial bronchodilator therapy. pH ***, PaCO2 ***, indicating *** respiratory acidosis with or without hypoxemia. Hemodynamic status: BP ***, HR ***, with ***.
This is acute respiratory failure superimposed on COPD exacerbation. Presentation is concerning for critical illness requiring advanced airway management consideration. Differential includes pneumonia, pulmonary embolism, acute coronary syndrome, and pneumothorax — imaging and labs address each.
If NIPPV candidate (alert, cooperative, pH >7.25, no acute coronary syndrome or contraindications): Noninvasive positive pressure ventilation (BiPAP) initiated with initial settings *** with goal to reduce work of breathing, improve ventilation, and allow time for medical therapy to take effect. Continuous pulse oximetry, frequent clinical reassessment, and repeat ABG in 30–60 minutes. Aggressive bronchodilator therapy continued (nebulizers may be delivered via NIPPV circuit if available).
If intubation required (NIPPV failure, inability to protect airway, altered mental status, or severe acidosis pH <7.25): Rapid sequence intubation performed. Post-intubation management includes low respiratory rate (8–10 breaths/min), prolonged expiratory time (allow full exhalation to prevent air trapping and auto-PEEP), and acceptance of higher CO2 levels (permissive hypercapnia) to minimize barotrauma.
Plan: ICU admission for continuous monitoring, serial ABGs, aggressive bronchodilator therapy, corticosteroids, and mechanical support. Antibiotics if infection component present. Disposition: ICU-level care with frequent reassessment for extubation readiness once exacerbation improves.
Clinical Education
Severity Assessment and GOLD Guidelines
COPD exacerbation severity is best assessed by respiratory mechanics and gas exchange, not by symptoms alone. The GOLD guidelines define exacerbation severity based on clinical presentation and physiologic parameters: mild exacerbations can be managed in the ambulatory setting, moderate exacerbations typically require ED evaluation and consideration for admission, and severe exacerbations present with respiratory failure and require ICU-level care.
Key physiologic parameters include respiratory rate (tachypnea >25 suggests moderate-to-severe exacerbation), accessory muscle use, ability to speak in full sentences (cannot speak indicates severe dyspnea), oxygen saturation on supplemental oxygen, and arterial blood gas parameters. The presence of respiratory acidosis (pH <7.35) indicates significant ventilatory impairment; pH <7.25 is associated with poor prognosis and high risk of intubation.
| Severity Grade | Clinical Features | Typical Setting |
| Mild | Increased symptoms, can speak sentences, RR 90% on room air or low-flow O2 | Outpatient/home management |
| Moderate | Significant dyspnea, RR 25–30, cannot speak sentences easily, O2 sat 88–92% on supplemental O2, no respiratory acidosis on ABG | ED evaluation; may discharge or admit depending on response to treatment |
| Severe | Respiratory distress at rest, cannot speak, RR >30, altered mental status, pH <7.35, PaCO2 elevated, may require mechanical support | ED and ICU admission |
Clinical pearl: The most common presentation to the ED is moderate exacerbation in a patient who is well appearing and responsive to initial therapy. Reassess after 1–2 hours of treatment; if the patient improves, discharge with close outpatient follow-up. If the patient deteriorates or does not improve, escalate care and consider ICU-level intervention.
Bronchodilator Therapy
Dual bronchodilator therapy (beta-2 agonist plus anticholinergic) is the foundation of COPD exacerbation treatment in the ED. The combination of albuterol and ipratropium in a single nebulizer treatment is more effective than either agent alone. [1]
Standard ED dosing is albuterol 5 mg + ipratropium 0.5 mg nebulized together every 30–60 minutes for the first 2–3 hours, then transition to every 2–4 hours based on clinical response. Continuous nebulization is an alternative for severe exacerbations but is no more effective than intermittent dosing and ties the patient to the nebulizer. Metered-dose inhalers (MDI) with spacer are equivalent to nebulizers in cooperative patients and allow earlier mobilization — 4 puffs albuterol (100 mcg/puff = 400 mcg) + 2 puffs ipratropium (20 mcg/puff = 40 mcg) via spacer is equivalent to standard nebulizer doses.
Peak bronchodilator response typically occurs 15–30 minutes after administration. Clinical reassessment at this timepoint (improved dyspnea, decreased RR, improved O2 sat, able to speak more comfortably) guides the need for repeat dosing. Failure to improve significantly after two cycles of therapy suggests either inadequate diagnosis or need for escalation to NIPPV or intubation.
Systemic Corticosteroids
Systemic corticosteroids reduce length of stay and speed recovery in COPD exacerbation; the REDUCE trial showed that a short course (prednisone 40 mg daily for 5 days) is as effective as longer tapers. [2] This finding has simplified prescribing and improved adherence — a fixed 5-day course is easier to communicate than a dose taper.
Standard dosing is prednisone 40 mg oral or methylprednisolone 125 mg IV daily. The choice between oral and IV is driven by clinical judgment: if the patient is nauseous or unable to take oral medication, IV is preferred. Prednisone 40 mg is a standard ED dose; higher doses (60 mg) do not improve outcomes and increase adverse effects. Hypokalemia and hyperglycemia are common side effects — check electrolytes, especially in patients with concurrent diuretic use, and monitor glucose in diabetic patients.
Initiate steroids as soon as the diagnosis is made; no need to wait for blood cultures or other tests. The REDUCE trial gave the drug on day 1, showing benefit within hours.
Antibiotics in COPD Exacerbation
Antibiotics are indicated in COPD exacerbation when there is evidence of bacterial infection: increased sputum purulence plus increased sputum volume, or the patient is on mechanical ventilation (to cover ventilator-associated pathogens). [3] Not all exacerbations are infectious; viral triggers are common, and unnecessary antibiotics increase resistance and adverse effects. The “increased sputum” criterion alone without change in character is insufficient.
First-line agents for uncomplicated exacerbations are azithromycin 500 mg oral daily for 3 days or doxycycline 100 mg oral twice daily for 5 days. Both achieve good lung penetration and cover typical pathogens: Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis. Fluoroquinolones (levofloxacin 750 mg daily) are reserved for patients with risk factors for complicated infection (advanced age, poor lung function FEV1 <50%, prior exacerbations, antimicrobial resistance concerns) or when beta-lactams are contraindicated.
Duration is typically 3–5 days for mild-to-moderate exacerbations. Longer courses do not improve outcomes and increase adverse effects. IV antibiotics are not superior to oral for uncomplicated exacerbations managed in the ED or floor setting; reserve IV for patients requiring ICU admission or unable to take oral medication.
NIPPV (BiPAP) and Respiratory Failure
Noninvasive positive pressure ventilation (BiPAP) is first-line for acute hypercapnic respiratory failure in COPD exacerbation and significantly reduces intubation rates and mortality. [4] Success rates exceed 70% in appropriately selected patients, and NIPPV allows continued medical therapy (bronchodilators, steroids) while taking work off the respiratory muscles.
NIPPV candidacy requires (1) alert, cooperative patient who can protect airway, (2) pH >7.25 (lower pH indicates more severe acidosis and higher intubation risk), (3) no contraindications (acute coronary syndrome, hemodynamic instability, uncontrolled arrhythmia). Relative contraindications include vomiting, inability to cooperate, or facial trauma.
Typical initial settings for COPD are IPAP 10–12 cm H2O and EPAP 5 cm H2O, titrated upward by 2–3 cm H2O every 5–10 minutes as tolerated to IPAP 15–18 cm H2O. The goal is to reduce respiratory rate, improve oxygenation, and normalize pH over 30–60 minutes. Repeat ABG 30–60 minutes after initiation to assess response. Continue aggressive bronchodilator therapy; nebulized medications can be administered through the NIPPV circuit in specialized setups or temporarily removed for nebulization.
Early failure indicators: Worsening pH despite 1–2 hours of NIPPV, inability to improve on NIPPV settings, patient exhaustion or refusal, or hemodynamic deterioration. Patients with pH <7.20 at presentation have higher intubation rates even with NIPPV and should be monitored very closely with a low threshold for intubation.
Intubation and Mechanical Ventilation
Intubation is indicated for NIPPV failure, inability to protect airway, severe respiratory acidosis (pH <7.20), altered mental status, or hemodynamic instability. COPD patients are at high risk for complications from mechanical ventilation (barotrauma, air trapping, auto-PEEP), so strategy emphasizes permissive hypercapnia and lung-protective ventilation.
Ventilator settings in COPD exacerbation prioritize low respiratory rate (8–10 breaths/min, not 12–16 as in other conditions) and prolonged expiratory time (I:E ratio 1:4 or longer, e.g., inspiratory time 1 second, expiratory time 4 seconds) to allow complete exhalation and prevent air trapping. This minimizes auto-PEEP (the pressure that builds when exhalation is incomplete). Higher minute ventilation leads to higher CO2, but in COPD, accepting PaCO2 35–50 (even up to 55–60 in severe cases) is standard practice to avoid barotrauma — this is permissive hypercapnia. [5]
Acid-base targets: target pH >7.20; do not attempt to normalize pH to 7.35–7.45 as this requires higher minute ventilation and barotrauma risk. Monitor for auto-PEEP by checking the expiratory hold maneuver (applied PEEP vs total PEEP). If auto-PEEP is high (>10 cm H2O), reduce respiratory rate further or increase expiratory time.
Sedation strategy avoids aggressive paralysis initially; maintain spontaneous effort if possible to preserve respiratory muscle function and ease weaning. Use benzodiazepines and opioids for sedation; avoid long-acting paralytics early unless needed for patient-ventilator dyssynchrony.
Disposition Criteria
Discharge criteria: Patient improves on bronchodilators and corticosteroids within 1–2 hours, achieves O2 saturation >90% on room air or modest supplemental oxygen, respiratory rate normalizes to <25, no signs of respiratory distress at rest, able to walk and perform activities of daily living, and able to take oral medications reliably. PCP or pulmonary follow-up should be arranged within 1 week. Return precautions include worsening dyspnea, inability to maintain oxygen saturation, fever, or new chest pain.
Admission criteria (floor bed): Partial response to initial therapy but not ready for discharge (e.g., still requiring frequent nebulizers, borderline oxygenation, or social barriers to follow-up within 24 hours). Floor admission allows 24–48 hours of continued therapy with close monitoring before discharge.
ICU admission: Respiratory failure on presentation or after ED trial of therapy (pH <7.35, PaCO2 elevated, altered mental status), need for NIPPV or intubation, hemodynamic instability, acute coronary syndrome or other life-threatening comorbidity, altered mental status, or severe comorbid illness.
Clinical pearl: Many patients improve dramatically after the first 1–2 hours of aggressive bronchodilators and steroids — this is the common pathway and reason to avoid excessive testing. Reassess clinically at 1 hour. If the patient is better and stable, discharge. If plateau or worsening, escalate: ICU evaluation, ABG, and consideration of NIPPV or intubation.
References
- Rodrigo GJ, Castro-Rodriguez JA. Anticholinergics in the treatment of COPD exacerbations: a systematic review with meta-analysis. Chest. 2006;129(3):571-580. PubMed
- Leuppi JD, Schuetz P, Bingisser R, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease. JAMA. 2013;309(21):2223-2231. PubMed
- Miravitlles M, Molina J, Naberan K, et al. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. Respir Med. 2008;102(7):1033-1041. PubMed
- Osadnik CR, Tee VS, Young IH, Philips G, Brabbas KH, Holland AE. Non-invasive ventilation for exacerbations of COPD: a systematic review and meta-analysis. Lung. 2015;193(5):639-650. PubMed
- Gajic O, Dabbagh O, Park PK, et al. Early identification and low-tidal-volume ventilation of acute lung injury and acute respiratory distress syndrome. Crit Care Med. 2007;35(5):1247-1253. PubMed
tydotphrase.com 